Study findings, published in Frontiers in Medicine, underscore the importance of metabolic profiling for discovering candidate screening biomarkers for interstitial lung disease (ILD) in rheumatoid ...
SAN DIEGO — A recent FDA approval for systemic sclerosis-associated interstitial lung diseases may portend a new hope for clinicians managing these complicated disorders, according to a presentation ...
Interstitial lung disease (ILD) is an umbrella term used for a group of diseases characterized by lung injury including pneumonitis, which can lead to irreversible lung fibrosis. ILD is a ...
More clinical guidance is needed for monitoring interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA), according to a new commentary. Though ILD is a leading cause of death among ...
Please provide your email address to receive an email when new articles are posted on . Newly announced ACR guidelines recommend against glucocorticoids as first-line therapy for interstitial lung ...
Patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) were 69% less likely to develop interstitial lung disease (ILD), compared with those treated with adalimumab (Humira), ...
Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc)-associated death, and there's increasing interest in patients with the ...
Nerandomilast improved FVC in the FIBRONEER-ILD trial, meeting its primary end point in patients with progressive pulmonary fibrosis. Safety and tolerability results were consistent with previous ...
Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing difficult. Early diagnosis is vital for effective management. Contributing factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback